Patient characteristics (age, gender, ITP duration, splenectomy status), TPO-RA regimens (TPO-RA types, starting doses, dosing algorithms, and treatment durations), and outcome of interest definitions varied among the included studies. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.